Image Sourced ShutterStock
Market Herald logo


Be the first with the news that moves the market
  • GI Dynamics has successfully contracted two United States Universities to begin trailing its product EndoBarrier
  • Trials for EndoBarrier in patients with type 2 diabetes and obesity will begin in the second half of 2019

Medical device company GI Dynamics has announced the execution of contracts with the first two sites for the trial of EndoBarrier. These will take place at the University of Michigan and Baylor College of Medicine in Texas.

The trial EndoBarrier, STEP-1 single therapy euglycemic procedure, will begin enrolling patients with type 2 diabetes and obesity during the second half of 2019. It will consist of randomised EndoBarrier implants and control arms with both receiving identical therapy.

The main goal of STEP-1 is to achieve a reduction in blood sugar levels after 12 months of treatment.

The University of Michigan runs one of the largest hospitals in Michigan and has been the site of groundbreaking medical and technological advancements in health care.

Principal investigator Allison Schulman hopes the study will be effective and bring an understanding to the conditions and treatments.

“I hope this study will prove safe and effective with the new protocol that GI Dynamics has developed,” she said.

Hosting over 75 speciality clinics Baylor College offers specialised care and provides patients with innovative treatments and therapies.

Baylor College’s principal investigator Wasif Abidi hopes that suffers of type 2 diabetes will see the positives of this treatment.

“EndoBarrier is a unique and innovative treatment option for type 2 diabetes and obesity that will be very attractive to many patients,” he said.

According to GI Dynamics Vice President Stephen Linhares: “it is imperative that each clinical site is equipped with the tools and knowledge to help STEP-1 be successful.”

GI Dynamics share price has remained steady since Friday June 7 at $1.70.

GID by the numbers
More From The Market Herald

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.